Please use this identifier to cite or link to this item: http://repository.kln.ac.lk/handle/123456789/23975
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRodrigo, T.
dc.contributor.authorSamaranayake, D.
dc.contributor.authorSeneviratne, S.N.
dc.contributor.authorde Silva, A.P.
dc.contributor.authorFernando, J.
dc.contributor.authorde Silva, H.J.
dc.contributor.authorJayasekera
dc.contributor.authorWickramasinghe, V.P.
dc.date.accessioned2021-11-29T09:45:54Z
dc.date.available2021-11-29T09:45:54Z
dc.date.issued2022
dc.identifier.citationClinical and Experimental Pediatrics.2022; 65(6):304-311 [Epub 2021 Nov 11]en_US
dc.identifier.issn2713-4148
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/23975
dc.descriptionIn PUBMED, Not indexed for MEDLINE; Not in SCI/SSCI/ESCIen_US
dc.description.abstractBackground: Childhood obesity is a global problem associated with metabolic abnormalities. The gut-liver axis is thought to play a major role in its pathogenesis. Probiotics are known to alter the gut microbiota and, therefore, could be a therapeutic option in the management of childhood obesity-related complications. Purpose: This double-blind randomized placebo-controlled trial evaluated the effects of probiotics on metabolic derangement in obese children with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Methods: Obese children with NAFLD/NASH treated at the nutrition clinic of the University Paediatric Unit at Lady Ridgeway Hospital, Colombo, were recruited. Anthropometry, body fat, metabolic derangement, and liver ultrasound scan (USS) results were evaluated at baseline and after 6 months. Transient elastography (FibroScan®) was performed on a subsample of these patients. Eighty-four patients were recruited and randomized into the probiotics (n = 43) and placebo (n = 41) groups. The mean age was 11.3±1.9 versus 12.1±1.5 years in the probiotic and placebo groups, respectively. Baseline parameters including liver disease stage on USS, body fat percentage, fasting blood sugar, lipid profile, liver function, and C-reactive protein showed no significant intergroup differences. Results: In the probiotic group, a statistically significant reduction in body mass index was noted from the baseline value. However, the reduction was not significant compared with the placebo group. There was a significant reduction in triglycerides, aspartate transaminase (AST), alanine aminotransferase (ALT), AST/ALT ratio, and alkaline phosphatase in the placebo group over the treatment period. Although the liver disease stage on USS improved from stage II-III to stage I in a small number of patients in the probiotic-treated group, transient elastography performed in a subsample did not demonstrate significant improvement in either group. Conclusion: Our results indicate that probiotics have no advantage over lifestyle modification for improving obesity-associated metabolic derangement in children.en_US
dc.language.isoenen_US
dc.publisherKorean Pediatric Societyen_US
dc.subjectMetabolic syndromeen_US
dc.subjectNAFLDen_US
dc.titleEffects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: a randomized clinical trialen_US
dc.typeArticleen_US
Appears in Collections:Journal/Magazine Articles

Files in This Item:
File Description SizeFormat 
cep-2021-00787 (1).pdf869.18 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.